PT  - JOURNAL ARTICLE
AU  - Radhakrishnan, Aditya
AU  - Spencer, Stephanie
AU  - Yanamala, Naveena
AU  - Malepati, Sarath
TI  - Evaluating the Utility of EZC Pak, a 5-Day Combination Echinacea-Zinc-Vitamin C Dose Pack with or without Vitamin D, in the Management of Outpatient Upper Respiratory Infections
AID  - 10.1101/2022.10.18.22280622
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.10.18.22280622
4099  - http://medrxiv.org/content/early/2022/10/20/2022.10.18.22280622.short
4100  - http://medrxiv.org/content/early/2022/10/20/2022.10.18.22280622.full
AB  - Background Growing antibiotic resistance is among the most serious threats to healthcare systems and public health globally with antibiotic misuse considered a leading driver of this problem. One of the largest areas of antibiotic misuse is in outpatient upper respiratory infections (URIs), the most common infection in humans. The purpose of this research is to evaluate the efficacy of EZC Pak, a combination Echinacea-Zinc-Vitamin C dose pack with or without Vitamin D, on the duration of illness and symptom severity of non-specific URIs as an alternative to antibiotics when none are deemed clinically necessary. A secondary analysis was carried out on patient satisfaction with using EZC Pak.Methods A total of 360 patients across the United States were enrolled and randomized in a double-blind manner across two intervention groups, EZC Pak, EZC Pak+Vitamin D, and one placebo group. The study was conducted virtually utilizing a smartphone-based app to screen, enroll and capture study data of the participants. Once a study participant reported the first symptoms of a URI, they were advised to take the intervention as directed and complete the daily symptom survey score until their symptoms resolved.Results The average EZC Pak participant recovered 1.39 days faster than placebo (p = 0.017) than the average placebo participant. The average EZC Pak participant reported a 17.43% lower symptom severity score versus placebo (p = 0.029). EZC Pak users reported 2.9 times higher patient satisfaction versus users of the placebo (p = 0.012). The addition of Vitamin D during this acute phase of illness neither benefited nor harmed illness duration or symptom severity.Conclusions The findings support the potential use of EZC Pak as a viable alternative to patient request for antibiotics when none are deemed clinically necessary at the time of initial clinical presentation. The decision to replete vitamin D in the acute phase of URI is an individualized decision left to the patient and their clinician. EZC Pak may play a critical role in improving outpatient URI management and antibiotic stewardship. (ClinicalTrials.gov number, NCT04943575.)Competing Interest StatementThis clinical trial was carried out by Citrus Labs with funding support from PPC Pharmaceuticals. Aditya Radhakrishnan received a stipend from PPC Pharmaceuticals for his participation in the study. Sarath Malepati is a shareholder in PPC Pharmaceuticals. Stephanie Spencer has no relevant financial disclosures. Naveena Yanamala has no relevant financial disclosures.Clinical TrialNCT04943575Funding StatementThis clinical trial was carried out by Citrus Labs with funding support from PPC Pharmaceuticals. Aditya Radhakrishnan received a stipend from PPC Pharmaceuticals for his participation in the study. Sarath Malepati is a shareholder in PPC Pharmaceuticals. Stephanie Spencer has no relevant financial disclosures. Naveena Yanamala has no relevant financial disclosures.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Argus Independent Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.